Now, compounds to boost effectiveness of antibiotics

Now, compounds to boost effectiveness of antibiotics

Image
Press Trust of India Washington
Last Updated : Oct 12 2018 | 8:21 PM IST
Scientists have developed compounds that can bolster the ability of antibiotics to treat deadly bacterial diseases such as MRSA and anthrax.

Researchers from the University of California, Irvine and Northwestern University built upon previous work in which they created compounds that inhibit an enzyme called neuronal nitric oxide synthase.

These have demonstrated the potential to treat neurodegenerative diseases by blocking overproduction of cell-killing nitric oxide within neurons.

Also Read

Now, the researchers are learning that the compounds may have another important function.

After UC Irvine's Thomas Poulos and Northwestern's Richard Silverman read a study suggesting that nitric oxide synthase helped pathogenic bacteria resist antibiotics, their laboratory teams paired the inhibitor compounds with currently used antibiotics to see if they could suppress nitric oxide synthase (NOS) - and increase the antibiotics' effectiveness.

"We found that NOS inhibitors were extremely successful at inhibiting neurodegeneration in an animal model, and if they could be successful combating other diseases, we wanted to identify that as quickly as possible to help other people," said Poulos.

The researchers tested their compounds on Bacillus subtilis, nonpathogenic bacteria very similar to Staphylococcus aureus (known as MRSA), and Bacillus anthracis, which causes anthrax.

Bacteria treated with the NOS inhibitors and an antibiotic were killed off more efficiently and completely than bacteria treated with only an antibiotic.

The scientists then compared the three-dimensional structure of the inhibitors bound to the bacterial NOS with those bound to the neuronal NOS and determined that they bonded quite differently.

"Now that we know which region of the NOS to target, we should to be able to develop compounds that selectively bind to bacterial NOS," Poulos said, adding that his team will also need to try out those compounds in animal models.

The study was published in the journal Proceedings of the National Academy of Sciences.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Nov 26 2013 | 3:46 PM IST

Next Story